
HER2 Testing Market [Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization (CISH) & Silver-enhanced in situ hybridization] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-203
Description
HER2 Testing Market [Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization (CISH) & Silver-enhanced in situ hybridization] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
HER2 Testing Market – Scope of Report
TMR’s report on the global HER2 Testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global HER2 Testing market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HER2 Testing market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the HER2 Testing market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HER2 Testing market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HER2 Testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HER2 Testing market.
The report delves into the competitive landscape of the global HER2 Testing market. Key players operating in the global HER2 Testing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HER2 Testing market profiled in this report.
Key Questions Answered in Global HER2 Testing Market Report
- What is the sales/revenue generated by HER2 Testing across all regions during the forecast period?
- What are the opportunities in the global HER2 Testing market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
HER2 Testing Market – Research Objectives and Research Approach
The comprehensive report on the global HER2 Testing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global HER2 Testing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HER2 Testing market.
Table of Contents
176 Pages
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary : Global HER2 Testing Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global HER2 Testing Market Analysis and Forecasts, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
- 5. Key Insights
- 5.1. Detailed Analysis of HER2 Expression in Gastric & Gastroesophageal Cancer
- 5.2. Breast and Gastric Cancer Prevalence & Incidence Rate globally with key countries
- 5.3. Regulatory Scenario
- 5.4. Key Industry Developments
- 5.5. Pipeline Analysis for Gastric Cancer
- 5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/Mid-/Long-term Impact)
- 6. Global HER2 Testing Market Analysis and Forecast, by Technique
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Technique, 2017-2031
- 6.3.1. Fluorescence in situ hybridization
- 6.3.2. Dual-probe
- 6.3.3. Single-probe
- 6.3.4. Chromogenic in situ hybridization (CISH)
- 6.3.5. Silver-enhanced in situ hybridization
- 6.4. Market Attractiveness, by Technique
- 7. Global HER2 Testing Market Analysis and Forecast, by Cancer Type
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Cancer Type, 2017-2031
- 7.3.1. Breast Cancer
- 7.3.2. Gastric Cancer
- 7.4. Market Attractiveness, by Cancer Type
- 8. Global HER2 Testing Market Analysis and Forecast, by End-user
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by End-user, 2017-2031
- 8.3.1. Hospitals
- 8.3.2. Diagnostic Laboratories
- 8.3.3. Others
- 8.4. Market Attractiveness, by End-user
- 9. Global HER2 Testing Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness, by Country/Region
- 10. North America HER2 Testing Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast, by Technique, 2017-2031
- 10.2.1. Fluorescence in situ hybridization
- 10.2.2. Dual-probe
- 10.2.3. Single-probe
- 10.2.4. Chromogenic in situ hybridization (CISH)
- 10.2.5. Silver-enhanced in situ hybridization
- 10.3. Market Value Forecast, by Cancer Type, 2017-2031
- 10.3.1. Breast Cancer
- 10.3.2. Gastric Cancer
- 10.4. Market Value Forecast, by End-user, 2017-2031
- 10.4.1. Hospitals
- 10.4.2. Diagnostic Laboratories
- 10.4.3. Others
- 10.5. Market Value Forecast, by Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Technique
- 10.6.2. By Cancer Type
- 10.6.3. By End-user
- 10.6.4. By Country
- 11. Europe HER2 Testing Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Technique, 2017-2031
- 11.2.1. Fluorescence in situ hybridization
- 11.2.2. Dual-probe
- 11.2.3. Single-probe
- 11.2.4. Chromogenic in situ hybridization (CISH)
- 11.2.5. Silver-enhanced in situ hybridization
- 11.3. Market Value Forecast, by Cancer Type, 2017-2031
- 11.3.1. Breast Cancer
- 11.3.2. Gastric Cancer
- 11.4. Market Value Forecast, by End-user, 2017-2031
- 11.4.1. Hospitals
- 11.4.2. Diagnostic Laboratories
- 11.4.3. Others
- 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Technique
- 11.6.2. By Cancer Type
- 11.6.3. By End-user
- 11.6.4. By Country/Sub-region
- 12. Asia Pacific HER2 Testing Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Technique, 2017-2031
- 12.2.1. Fluorescence in situ hybridization
- 12.2.2. Dual-probe
- 12.2.3. Single-probe
- 12.2.4. Chromogenic in situ hybridization (CISH)
- 12.2.5. Silver-enhanced in situ hybridization
- 12.3. Market Value Forecast, by Cancer Type, 2017-2031
- 12.3.1. Breast Cancer
- 12.3.2. Gastric Cancer
- 12.4. Market Value Forecast, by End-user, 2017-2031
- 12.4.1. Hospitals
- 12.4.2. Diagnostic Laboratories
- 12.4.3. Others
- 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Technique
- 12.6.2. By Cancer Type
- 12.6.3. By End-user
- 12.6.4. By Country/Sub-region
- 13. Latin America HER2 Testing Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Technique, 2017-2031
- 13.2.1. Fluorescence in situ hybridization
- 13.2.2. Dual-probe
- 13.2.3. Single-probe
- 13.2.4. Chromogenic in situ hybridization (CISH)
- 13.2.5. Silver-enhanced in situ hybridization
- 13.3. Market Value Forecast, by Cancer Type, 2017-2031
- 13.3.1. Breast Cancer
- 13.3.2. Gastric Cancer
- 13.4. Market Value Forecast, by End-user, 2017-2031
- 13.4.1. Hospitals
- 13.4.2. Diagnostic Laboratories
- 13.4.3. Others
- 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Technique
- 13.6.2. By Cancer Type
- 13.6.3. By End-user
- 13.6.4. By Country/Sub-region
- 14. Middle East & Africa HER2 Testing Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Technique, 2017-2031
- 14.2.1. Fluorescence in situ hybridization
- 14.2.2. Dual-probe
- 14.2.3. Single-probe
- 14.2.4. Chromogenic in situ hybridization (CISH)
- 14.2.5. Silver-enhanced in situ hybridization
- 14.3. Market Value Forecast, by Cancer Type, 2017-2031
- 14.3.1. Breast Cancer
- 14.3.2. Gastric Cancer
- 14.4. Market Value Forecast, by End-user, 2017-2031
- 14.4.1. Hospitals
- 14.4.2. Diagnostic Laboratories
- 14.4.3. Others
- 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Technique
- 14.6.2. By Cancer Type
- 14.6.3. By End-user
- 14.6.4. By Country/Sub-region
- 15. Competition Landscape
- 15.1. Market Player – Competition Matrix (By Tier and Size of companies)
- 15.2. Market Share Analysis By Company (2022)
- 15.3. Company Profiles
- 15.3.1. Abbott
- 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.1.2. Product Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Strategic Overview
- 15.3.2. Hoffmann-La Roche Ltd
- 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.2.2. Product Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Strategic Overview
- 15.3.3. Agilent Technologies, Inc.
- 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.3.2. Product Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Strategic Overview
- 15.3.4. Thermo Fisher Scientific, Inc.
- 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.4.2. Product Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Strategic Overview
- 15.3.5. Leica Biosystems (Danaher Corporation)
- 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.5.2. Product Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Strategic Overview
- 15.3.6. Empire Genomics, Inc. (Biocare Medical, LLC)
- 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.6.2. Product Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Strategic Overview
- 15.3.7. Bio-Genex Laboratories
- 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.7.2. Product Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Strategic Overview
- 15.3.8. Abnova Corporation
- 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.8.2. Product Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Strategic Overview
- 15.3.9. Oxford Gene Technology IP Limited (Sysmex Corporation)
- 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.9.2. Product Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Strategic Overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.